Cycle on Jun 8, 2026

I will start by listing the topic's open threads to see if there are any outstanding questions or registered watches that we need to address or update in this cycle.

I will fetch the market views for Eli Lilly (LLY) and Novo Nordisk (NVO) to get their latest financial metrics, stock performance, and recent news summaries.

I will now pull the market view for Novo Nordisk (NVO) to get its latest performance numbers.

I see several major clinical and market developments from the American Diabetes Association (ADA) 2026 Scientific Sessions, which seem to have just taken place or are currently taking place (June 5-7, 2026). Key items to investigate: 1. Eli Lilly's "next-gen obesity drug curbs sleep apnea, among other benefits" - retatrutide sleep apnea and knee osteoarthritis pain data. 2. Novo Nordisk's "Wegovy pill prescriptions surpass 3 million, bringing GLP-1 therapy to people with obesity... while Novo Nordisk unveils new data at ADA 2026". 3. Novo Nordisk's "zenagamtide (also known as amycretin) shows 14.6% weight-loss in mid-stage diabetes study" presented at ADA 2026. 4. "Lilly and Novo face off at ADA 2026 as others seek to compete in obesity". Let's do some web searches to fetch the actual articles or press releases for these announcements to gather concrete details, quotes, and links. I will search for the ADA 2026 presentations of Eli Lilly (retatrutide) and Novo Nordisk (zenagamtide/amycretin and oral Wegovy). Let's start with a search on "retatrutide sleep apnea osteoarthritis ADA 2026".

I will fetch the PR Newswire press release from Eli Lilly on retatrutide, which has comprehensive details on the Phase 3 (or late-stage) data presented at ADA 2026. Wait, let's look at the title of the first PR Newswire result: `https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-knee-osteoarthritis-pain-and-obstructive-sleep-apnea-demonstrating-its-remarkable-potential-to-treat-obesity-and-its-complications-302793169.html`. Let's fetch that. I will also fetch the Reuters article `https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-says-next-gen-obesity-drug-curbs-sleep-apnea-among-other-benefits-2026-06-06/` or the Drug Discovery Trends article. Let's start with the Lilly PR Newswire release.

This is a major development! Retatrutide is Eli Lilly's GIP/GLP-1/Glucagon ("triple agonist") molecule. The Phase 3 results (TRIUMPH-1 and TRANSCEND-T2D-1 trials) presented at ADA 2026 show massive weight loss (28.3% average weight loss at 12 mg over 80 weeks in TRIUMPH-1, and 30.3% in a pre-specified extension, which is the highest weight loss seen to date for any obesity therapeutic). It also showed massive improvements in comorbidities: a 73.1% reduction in knee osteoarthritis pain and a 60.6% reduction in sleep apnea severity (36.1 events per hour). Let's find out more about the status of retatrutide's clinical program. The trials mentioned are Phase 3 trials: TRIUMPH-1 and TRANSCEND-T2D-1. Wait, let me verify if they are Phase 3 or Phase 2/3. Let's do a web search on that. Or read the Drug Discovery Trends article. Let's search `retatrutide triumph-1 transcend-t2d-1 phase 3`.

This is excellent. Let's fetch the Lilly Investor relations press release `https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss` or `https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant` to get the exact verbatim details. Let's do a search to make sure we can fetch one of Lilly's actual press releases. Or we can fetch the TCTMD or Pharmacy Times article. Let's fetch the Pharmacy Times article `https://www.pharmacytimes.com/view/retatrutide-delivers-bariatric-level-weight-loss-pivotal-phase-3-triumph-1-trial` or the Lilly investor relations page. Let's fetch the Pharmacy Times one.

Excellent. Retatrutide's Phase 3 TRIUMPH-1 trial results show: - Mean weight reduction at 80 weeks was 28.3% (70.3 lbs) with the 12 mg dose, 25.9% (64.4 lbs) with 9 mg, and 19.0% (47.2 lbs) with 4 mg. - 45.3% of participants on 12 mg achieved 30% or greater weight loss (approaching bariatric surgery levels). - 65.3% of participants on 12 mg achieved a BMI below 30. - For patients continuing in a prespecified blinded extension, those with a baseline BMI of 35 or higher who remained on 12 mg through 104 weeks lost an average of 85.0 lbs (30.3%). This is unprecedented. - Common adverse events were gastrointestinal (nausea 42.4%, diarrhea 32.0%, vomiting 25.3%, constipation 26.1% in TRIUMPH-1). Discontinuation rates due to AEs were 11.3% for the 12 mg dose. - Lilly plans to submit regulatory applications for retatrutide in 2026. Let's search for "zenagamtide ADA 2026" or "amycretin diabetes ADA 2026" to get the details on Novo Nordisk's experimental oral/subcutaneous molecule zenagamtide (also known as amycretin). Let's do that search.

Let's fetch the PR Newswire press release for zenagamtide: `https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.html`. This will have the official trial numbers and quotes. I also want to see if we can find some other details on CagriSema data presented at ADA 2026. Let's fetch that PR Newswire first.

This is very interesting. Zenagamtide (amycretin) is a unimolecular peptide agonist of GLP-1 and amylin receptors. The phase 2 trial of once-weekly subcutaneous zenagamtide in adults with type 2 diabetes (T2D) met its primary endpoint, showing: - Up to 1.71% reduction in A1C at week 36 with the 40 mg dose from a baseline of 7.8%. - Up to 89.1% of participants achieved A1C below 7%. - Up to 14.6% weight loss in 36 weeks at the 40 mg dose (compared to 2.1% in placebo). - Common adverse events were GI (mild to moderate). - A Phase 3 development program for T2D is planned to initiate in H2 2026. - Zenagamtide is under investigation for both oral and subcutaneous administration. Let's look for CagriSema phase 3 data at ADA 2026. CagriSema is a combination of cagrilintide (amylin analogue) and semaglutide (GLP-1). Let's search "CagriSema ADA 2026 REIMAGINE" or "CagriSema Phase 3 ADA 2026".

This is amazing. Let's fetch the BioSpace press release or the Drugs.com page for CagriSema REIMAGINE 2: `https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-superior-hba1c-reduction-of-1-91-points-and-weight-loss-of-14-2-in-adults-with-type-2-diabetes-in-the-reimagine-2-trial` or `https://www.drugs.com/clinical_trials/cagrisema-demonstrated-superior-hba1c-reduction-1-91-points-weight-loss-14-2-adults-type-2-diabetes-22290.html`. Let's fetch the Drugs.com page first. Wait, let's fetch the Biospace one as it seems to be the official press release. Let's do that. Or let's fetch `https://www.prnewswire.com/news-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions-302783110.html` which is Novo's overview of CagriSema and zenagamtide. Let's fetch that.

Ah, the fetch failed with a timeout. Let's try fetching the Biospace one (`https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-superior-hba1c-reduction-of-1-91-points-and-weight-loss-of-14-2-in-adults-with-type-2-diabetes-in-the-reimagine-2-trial`) or search again to find a more reliable URL or try fetching the Drugs.com one. Let's fetch the Drugs.com one first to see if it loads.

Excellent. This provides the exact trial details for CagriSema in type 2 diabetes. Let's note that REIMAGINE 2 was indeed presented at ADA 2026 (as mentioned in the earlier search results: "Looking forward to presenting the results of the REIMAGINE 2 study at American Diabetes Association 2026 Congress..."). The Drugs.com article was published on February 2, 2026 (headline results announcement), and the full data was presented at ADA 2026. Let's see if there are any other presentations or trials from other competitors like Viking Therapeutics or Structure Therapeutics at ADA 2026. Let's do a search on "Viking Therapeutics ADA 2026" and "Structure Therapeutics ADA 2026".

Oh! Look at the Biospace article: `https://www.biospace.com/Lilly-Novo-face-off-at-ADA-2026-as-others-seek-to-compete-in-obesity` or `Lilly and Novo face off at ADA 2026 as others seek to compete in obesity`. Let's search for that to get its exact URL and content. This will be a perfect source for the overall competitive landscape from ADA 2026. Let's also look at Viking's announcement on VK2735: "Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026" on `https://www.prnewswire.com/news-releases/viking-therapeutics-presents-data-from-its-13-week-phase-2-venture-oral-dosing-trial-of-vk2735-at-european-congress-on-obesity-eco-2026-302768959.html`. This seems to have happened in May 2026 (very recently!). Let's search for this and fetch it. First, let's search for the Biospace article.

Let's fetch the BioSpace article: `https://www.biospace.com/Lilly-Novo-face-off-at-ADA-2026-as-others-seek-to-compete-in-obesity`. This is a crucial article summarizing ADA 2026 and the competitive landscape. Let's fetch it.

This is an incredibly rich article with massive amounts of competitive data from ADA 2026 and the overall landscape. Let's analyze the key details: 1. **Industry Dynamics**: IQVIA forecasts $92 billion in sales of obesity medicines in 2026 and up to $200 billion by 2027 and beyond. In 2025, obesity unseated oncology as the top contributor of pharma pipeline value (accounting for 25% of overall pipeline value). 2. **Eli Lilly**: - Presented Phase 3 TRIUMPH-1 (obesity) and TRANSCEND-T2D-1 (diabetes) data for its triple agonist (GIP/GLP-1/glucagon) **retatrutide**. - Retatrutide generated 28.3% weight loss over 80 weeks in TRIUMPH-1 (likened to bariatric surgery). - In December 2025, Phase 3 TRIUMPH-4 showed 26.6% placebo-adjusted weight loss at 68 weeks in patients with obesity/overweight and knee osteoarthritis. - However, safety concerns include **dysesthesia** (neurological anomaly of unpleasant/painful sensations) in over 20% of patients on the 20-mg dose in TRIUMPH-4, and also present in TRIUMPH-1 (rates rose with dose). 3. **Novo Nordisk**: - Presented next-gen **CagriSema** (fixed dose combination of semaglutide + long-acting amylin analog cagrilintide) in diabetes (Phase 3 REIMAGINE 1, 2, 3 trials). - Note: CagriSema failed to demonstrate non-inferiority to Lilly's Zepbound in obesity (REDEFINE-4 head-to-head study in Feb 2026 showed CagriSema patients lost 23% body weight on average at 84 weeks vs 25.5% for Zepbound). - Still, Novo expects CagriSema to hit U.S. shelves in early 2027 (or early 2026? Wait, the quote says: "When CagriSema will make it to the market early next year as the first amylin-based product, it will have the best weight loss label than any product marketed at that time," CEO Maziar Mike Doustdar said in early 2026, meaning it expects launch in early 2027. Wait, actually the quote says "early next year" referring to 2027). - Submitted CagriSema for weight management to FDA in December 2025 based on REDEFINE 1 & 2. 4. **Third-Place Contenders**: - **Boehringer Ingelheim & Zealand Pharma**: **survodutide** (GLP-1/glucagon receptor agonist). Presented Phase 3 SYNCHRONIZE-1 study at ADA 2026: 16.6% drop in weight at 76 weeks vs 3.2% in placebo. BMO noted this is less competitive vs tirzepatide but survodutide offers better quality weight loss (mostly fat loss, very little lean mass loss). Also targeting MASH. - **Roche**: **CT-388** (GLP-1/GIP receptor agonist, acquired from Carmot Therapeutics for $2.7B in late 2023). Presented detailed Phase 2 data at ADA 2026: 22.5% placebo-adjusted weight reduction at 48 weeks with no plateau. Roche plan to combine CT-388 with Zealand's amylin therapy petrelintide (under a $5.3B partnership signed in March 2025). - **Amgen**: **MariTide** (bispecific antibody-peptide targeting GLP-1/GIP). Phase 2 data in Nov 2024 showed up to 20% weight loss at 52 weeks (disappointing to some). Positioned as monthly/less frequent dosing. No data presented at ADA 2026, but Amgen was present. 5. **Smaller Biotechs**: - **Structure Therapeutics**: **aleniglipron** (oral GLP-1 pill). Presented Phase 2b ACCESS II study details at ADA 2026. In Dec 2025, 36-week data showed 11.3% placebo-adjusted weight loss. In March 2026, 44-week follow-up showed 16.3% placebo-adjusted weight loss. Also presented posters looking at lower starting doses and aleniglipron paired with an amylin asset. - **Viking Therapeutics**: **VK2735** (GIP/GLP-1 dual agonist, subQ and oral). Presented VENTURE-Oral Phase 2 data in May 2026 (European Congress on Obesity) showing 10.9% placebo-adjusted weight reduction at 13 weeks. SubQ VK2735 is in late-stage development (Phase 3), and oral formulation is scheduled to enter Phase 3 later in 2026. Let's do a search on "Wegovy oral tablet 3 million prescriptions Novo Nordisk ADA 2026" to find the exact details on the Wegovy oral tablet launch and data presented at ADA 2026. This was mentioned in NVO's news: "Wegovy pill prescriptions surpass 3 million, bringing GLP-1 therapy to people with obesity... while Novo Nordisk unveils new data at ADA 2026". Let's search for this.

This is highly informative! The Wegovy pill (oral semaglutide) was approved by the FDA and launched in the U.S. in early January 2026 (Jan 5, 2026). Let's see: - "More than 2 million prescriptions have now been written for the Wegovy pill, which launched on Jan. 5, Novo said. The product had more than..." (biopharmadive.com, Q1 2026). - "Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated... while Novo Nordisk unveils new data at ADA 2026" (June 2026). - "Our FDA-approved GLP-1 weight loss medicine has already surpassed three million prescriptions in the US since its launch — making it one of..." - "Wegovy® pill (1.5 mg) is available for only $149 per month (or $5 per day) via an easy to access self-pay offer available at Wegovy.com." - "Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026." Wait, let's fetch the BioPharma Dive article `https://www.biopharmadive.com/news/novo-nordisk-wegovy-pill-sales-prescriptions-q1-2026/819418/` or do a search for the exact press release on Wegovy pill prescriptions surpassing 3 million in June 2026 to get the exact quotes. Let's search `Wegovy pill prescriptions surpass 3 million Novo Nordisk June 2026`.

Let's fetch the BioPharma Boardroom article `https://www.biopharmaboardroom.com/company-results/64/4678/-novo-nordisk-raises-2026-outlook-as-wegovy-pill-delivers-record-glp-1-launch-performance.html` or the Yahoo Finance article `https://finance.yahoo.com/sectors/healthcare/articles/wegovy-pill-prescriptions-surpass-3-120000897.html` (which is likely a reprint of the press release from June 7, 2026). Let's try to fetch `https://finance.yahoo.com/sectors/healthcare/articles/wegovy-pill-prescriptions-surpass-3-120000897.html` first. If that fails, I can look for another source or search for the exact text of the Novo Nordisk press release on June 7, 2026. Let's fetch it.

The Yahoo Finance URL timed out as well. Let's try fetching the BioPharma Boardroom article: `https://www.biopharmaboardroom.com/company-results/64/4678/-novo-nordisk-raises-2026-outlook-as-wegovy-pill-delivers-record-glp-1-launch-performance.html`. Let's fetch that.

This is a goldmine of financial and commercial data for Novo Nordisk! Let's examine the details of this Q1 2026 earnings report (published on May 7, 2026): 1. **Wegovy Pill Launch**: - Launched in the US on January 5, 2026. - For the week ending April 17, 2026, total weekly prescriptions exceeded 200,000. - Total prescriptions for Q1 2026 were around 1.3 million, and had reached more than 2 million by May 2026 (and as of June 7, 2026, it surpassed 3 million prescriptions, filled roughly every 5 seconds). - Q1 2026 sales for Wegovy® pill reached DKK 2,256 million (~$325 million USD), impacted by pre-launch pipeline fill with wholesalers and telehealth partners. - First launches outside the US are expected during H2 2026. - Self-pay offer: $149/month or $5/day via Wegovy.com (for the 1.5 mg dose). 2. **Wegovy HD Approval**: - Wegovy HD (injectable semaglutide 7.2 mg) was approved by the FDA in March 2026 and launched in the US on April 7, 2026. - In the STEP UP trial, Wegovy HD provided 20.7% mean weight loss. 3. **Financials & 340B Program Provision Reversal**: - Q1 2026 reported sales increased by 32% at CER (Constant Exchange Rates) to DKK 96,823 million (~$13.9 billion USD). - Q1 2026 reported operating profit increased by 65% at CER to DKK 59,618 million (~$8.6 billion USD). - This massive reported growth was positively impacted by a **DKK 29.2 billion / USD 4.2 billion non-recurring impact from a provision reversal related to the 340B Drug Pricing Program in the US**. - Excluding this 340B provision reversal, adjusted sales in Q1 2026 actually decreased by 4% at CER to DKK 70,063 million, driven by lower realized prices, partly offset by GLP-1 volume growth. - Adjusted Obesity care sales increased by 22% at CER. - Adjusted operating profit decreased by 6% at CER to DKK 32,858 million. - US Operations adjusted sales decreased by 11% at CER, driven by lower realized prices (net pricing declines), despite volume growth. 4. **Pipeline**: - Initiated the **zenagamtide AMAZE Phase 3 programme** for obesity. - Approved **Awiqli®**, the first once-weekly basal insulin for type 2 diabetes. Let's do a search on "Eli Lilly Q1 2026 earnings" to see if there is a similar level of detail on LLY's sales, pricing, and volumes. We saw in LLY's market view that Q1 2026 revenue was $19.80 billion, marking a 55.5% YoY increase, and net income was $7.40 billion (EBITDA $9.36B, operating income $8.85B). Let's search on "Eli Lilly Q1 2026 earnings sales Zepbound Mounjaro Foundayo" to get the product-specific sales and management commentary.

This is incredible! Let's fetch the PR Newswire release for Eli Lilly's Q1 2026 earnings (`https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines-302758113.html`) or the BioPharma Dive article (`https://www.biopharmadive.com/news/lilly-q1-2026-earnings-foundayo-zepbound-obesity/818912/`). Let's fetch the BioPharma Dive article first. This will give us the details on the blowout quarter, product sales, and the Foundayo launch.

This is exceptional! We have highly specific data on Eli Lilly's Q1 2026 financial results and market share: - Q1 2026 overall revenue surged 56% to $19.8 billion (beating expectations by over $2 billion). - Net income more than doubled to $7.4 billion (or $8.26/share). Non-GAAP EPS was $8.55 (beating the $6.77 consensus). - Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion, with non-GAAP EPS of $35.50 to $37.00. - **Market Share**: Lilly controls **just over 60% of the U.S. market** for GLP-1 medicines, compared with 39.4% for Novo Nordisk. - **International Market**: Lilly has taken the lead in the international market with **53.2% share** compared to 46.8% for Novo Nordisk. - **Product Sales**: - **Mounjaro** (including Zepbound for obesity) sales more than doubled to **$8.7 billion** in Q1 2026 (more than half from overseas). - Wait, let's verify if $8.7B is Mounjaro alone or Mounjaro + Zepbound. Let's look at the text: "Sales of Mounjaro, sold as Zepbound for obesity, more than doubled to $8.7 billion in the first quarter, with more than half of that revenue coming from overseas." Wait, actually another bullet says: "Mounjaro generated $8.7bn for the quarter, while Zepbound made $4.2bn." Let's check the Lilly press release search results: "For Q1 2026, worldwide Mounjaro revenue increased 125% to $8.7 billion. U.S. revenue was $4.2 billion..." Yes, Mounjaro is $8.7B and Zepbound is $4.2B. Let's verify that. That means Lilly's total tirzepatide sales (Mounjaro + Zepbound) reached $12.9 billion in a single quarter! - **Foundayo (Orforglipron) Launch**: - Approved on April 1, 2026. - Initial prescription numbers faced some skepticism, but Lilly reported that **80% of Foundayo prescriptions are for patients new to the GLP-1 drug class** (alleviating cannibalization concerns). - CEO David Ricks stated: "For people who want to lose 30 pounds, that’s going to be a great solution... We're seeing growth acceleration with price cuts." - Lilly plans to seek U.S. approval for Foundayo as a treatment for diabetes in the coming weeks (as of late April 2026). Wait, let's also look at the CVS Caremark formulary decision mentioned in one of the storyline links: "CVS obesity drug deal puts Lilly on equal footing with Novo" (published May 28, 2026). This directly relates to the brief's request: "pricing and reimbursement changes, formulary decisions by major PBMs and insurers". Let's search on "CVS Caremark formulary Zepbound Foundayo obesity Novo May 2026" or fetch `https://www.biopharmadive.com/news/lilly-cvs-caremark-formulary-zepbound-foundayo-obesity-glp1/821327/`. Let's fetch that. This is a crucial commercial update!

I will write the first research note detailing Eli Lilly's Q1 2026 financial performance, its market share leadership over Novo Nordisk, and its major formulary victory with CVS Caremark.

I will now write a note documenting Novo Nordisk's Q1 2026 financial results, which included a massive $4.2 billion non-recurring provision reversal, and the record-breaking commercial launch performance of its oral Wegovy pill.

I will write a research note on Eli Lilly's next-generation triple agonist retatrutide, detailing its monumental Phase 3 TRIUMPH-1 and TRANSCEND-T2D-1 clinical data presented at ADA 2026.

I will now write a research note on Novo Nordisk's pipeline developments presented at ADA 2026, specifically the Phase 3 REIMAGINE 2 data for CagriSema and the newly launched Phase 2 data for subcutaneous zenagamtide (amycretin).

I will now write a final note detailing the broader competitive landscape and other third-place contenders (Boehringer Ingelheim/Zealand Pharma, Roche, Amgen, Viking Therapeutics, and Structure Therapeutics) as of the ADA 2026 conference.